Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMansoura University

About this trial

Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.

Eligibility criteria

Qualifiers

Patients between 18 and 70 years of age

Patients mild (GCS 13-15) to moderate (GCS 9-12) TBI were assessed for the study eligibility.

Disqualifiers

Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours.

Acute or chronic renal insufficiency.

Hepatic diseases.

Autoimmune diseases.

Trial design

Treatments tested in this trial

  • Memantine
  • Mannitol

Treatment groups

80 Participants
are divided into 2 treatment groups

Sponsors and collaborators